Cost Per Responder Analysis from the Checkmate 025 Phase III Trial of Nivolumab Versus Everolimus in Previously Treated Patients with Advanced Renal Cell Carcinoma
May 1, 2016, 00:00 AM
10.1016/j.jval.2016.03.1562
https://www.valueinhealthjournal.com/article/S1098-3015(16)01630-2/fulltext
Section Title :
Cancer - Cost Studies
Section Order :
281
First Page :
A145
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01630-2&doi=10.1016/j.jval.2016.03.1562